25 July 2023
25 July 2023
The notion of outsourcing has changed over the years as sponsors are regaining their control with hybrid outsourcing models.
Chinese Academy of Sciences took the lead in grants received over Q2 2023 with top therapy area being severe acute respiratory syndrome.
AbbVie has started a Phase III trial of upadacitinib, also known as RINVOQ, in adults and adolescents with hidradenitis suppurativa.
Shares in the company dropped by 29% despite assurances the failure would not harm its 2023 financial outlook.
Evaluating the drug's safety profile and determining the maximum tolerated dose is the trial's primary objective.
Interim results from the trial are expected around the first quarter of next year.
TNG260 inhibits the Co-repressor of Repressor Element-1 Silencing Transcription complex.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
